Current treatments for intestinal diseases including inflammatory bowel diseases, irritable bowel syndrome, and colonic bacterial infections are typically small molecule oral dosage forms designed for systemic delivery. The intestinal permeability hurdle to achieve systemic delivery from oral formulations of macromolecules is challenging, but this drawback can be advantageous if an intestinal region is associated with the disease. There are some promising formulation approaches to release peptides, proteins, antibodies, antisense oligonucleotides, RNA, and probiotics in the colon to enable local delivery and efficacy. We briefly review colonic physiology in relation to the main colon-associated diseases (inflammatory bowel disease, irritable bowel syndrome, infection, and colorectal cancer), along with the impact of colon physiology on dosage form design of macromolecules. We then assess formulation strategies designed to achieve colonic delivery of small molecules and concluded that they can also be applied some extent to macromolecules. We describe examples of formulation strategies in preclinical research aimed at colonic delivery of macromolecules to achieve high local concentration in the lumen, epithelial-, or subepithelial tissue, depending on the target, but with the benefit of reduced systemic exposure and toxicity. Finally, the industrial challenges in developing macromolecule formulations for colon-associated diseases are presented, along with a framework for selecting appropriate delivery technologies.
Introduction
Oral dosage formulation designed for controlled release in the lower part of the small intestine and the colon to treat region-associated diseases has been achieved for a range of small molecules, but not yet for macromolecules [1] . The main colonic disease targets for both smalland macromolecules are inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), while to a lesser extent there are formulations aimed at diverticulosis, colonic amoebiasis, and irritable bowel syndrome (IBS) [2] . Unlike UC, CD and IBS are not restricted to the colonic region, but they typically involve colonic pathology as a part of their overall signature, as do enteric infectious disease and colon cancer for which there are no oral colonic release products to date. One aim of this review is to determine whether macromolecules can also be targeted to the colon for local delivery using the same technologies that have been designed for small molecules, or whether there is a need for alternative technologies designed to protect these labile payloads and to deliver them to the region more accurately. Our macromolecule definition covers amino-acid based therapeutics (e.g., peptides, proteins, antibodies), and nucleic acid-based structures (e.g. antisense oligonucleotides, siRNA, mRNA, CRISPR-Cas-9). Though not macromolecules per se, probiotics and bacteria are included for their potential as cell-based vectors to release macromolecules in the colon.
Our starting point is a list of oral macromolecules for local gastrointestinal tract (GI) therapy which, according to public domain resources, were in clinical development in 2016 [3] . We have updated it here and have restricted inclusion to colonic targeting ( Table 1 ). The group includes: stable cyclic peptides of b2000 Da in molecular weight (MW) to treat constipation associated-IBS (IBS-C), as well as macrocycle antibiotics to treat chlostridium difficile (C. diff.) and staphylococcal enteric infections. Also included in Table 1 are a range of approaches to treat IBD: an antibody against tumor necrosis factor (TNF)-α, bacteria that secrete interleukin (IL)-10, as well as several modified stable antisense oligonucleotides. Of these, selected macrocycle peptides predicated on the structure of linaclotide (to treat IBS-C) and on the structure of vancomycin (to treat enteric infections) have been approved by the FDA, whereas the outcomes for oral antibodies and oligonucleotides in pivotal clinical trials remains to be seen. Local delivery of macromolecules through oral formulation might be regarded as being more achievable than systemic delivery since it is not constrained by having to include formulation components to address low permeability, where there are perceived concerns over possible toxicity and immunogenicity of both the payload and permeation enhancement components of the dosage form [3] . Irrespective, the labile nature of the macromolecule must also be addressed by both systemic and local delivery approaches. In addition, local delivery of macromolecules to the colon has its own formulation challenges, including variability in targeting the colon due to intra-subject GI physiology differences, which can be accentuated by disease, gender, age, and diet. Secondly, an assumption is often made that targeting of macromolecules will automatically be achieved if regional delivery to the colon can be accomplished by a formulation: this might be true for antibiotics with actions in the lumen. For macromolecules acting at the epithelium, however, there is still the barrier of the overlying mucus layer to overcome [4] . For other macromolecules, the target is more likely to be within the epithelial monolayer or the submucosa, so there is a requirement for epithelial cell apical membrane permeability followed by intracellular drug release to bind the intended receptor, but with limited permeability across the basolateral membrane. Here, we assess several of the approaches and technologies for delivering a range of macromolecule classes to the colonic region for several diseases, but with a focus on IBD. Fig. 1 . presents the molecules that are approved for the different grades of UC or CD, and it is apparent that macromolecules comprise the majority assigned to moderate-tosevere cases. It is important to also note that most formulation strategies for colonic delivery of macromolecules in clinical development outlined are typically limited to simple enteric-coated capsules, granules or tablets, likely due to their track record in delivering small molecules to the colonic region.
of up to 1.5 m, compared to the 6.0 m length of the small intestine. While the small intestine is designed to absorb essential nutrients using emulsification, a high epithelial surface area for absorption, and receptor systems, the colon has a dominant role in maintaining water balance, supporting the inter-dependent microbiome, and the production of faeces. Its milieu is complex: a semi-solid mass of faeces, volatile short chain fatty acids, methane, and carbon dioxide, minerals, salts, water, as well as very high concentrations of up to 1800 microbial species, with predominantly anaerobic bacteria at densities of up to 10 12 CFU/g in the caecum and colon [5] . Microvilli are present on transverse furrows of the colon and they comprise 1.2 m 2 surface area of epithelia designed for electrogenic chloride secretion and/or sodium absorption, closely associated with the passive diffusion of ions and water to maintain osmolarity. The luminal fluid of the normal colon has a wide pH range of 5.5-8.0 across its four parts [6] , values than can overlap with that of the latter part of the small intestine; this variability has implications for achieving reproducible colonic release from dosage forms with pH-dependent coatings. Within the colonic regions, pH tends to rise from 6.4 (ascending colon, due to contribution by short chain fatty acids), to 6.6 (transverse colon), and to 7.0 (descending colon) [7] , but there is large intra-and inter-subject variability across these values. Colonic transit is slow and variable, ranging from 24 to 42 h, depending on dietary composition (e.g. meat-eaters versus vegetarian), with possible differences between male and female, thereby reducing the accuracy of delivery systems based on time-based release for a population. This compares to the somewhat more predictable 3-4 h mean range for small intestinal transit, although there is also variability in that figure. As the composition of the colon lumen comprises a high percentage of gas and semi-solid materials, fluid volume is estimated at just 13 ml in the healthy colon [8] and this reduces capacity to reproducibly dissolve colonic dosage forms. In studies of how colonic physiology changes with age, compromised levels of colonic neurotransmission and low production of nitric oxide reduce peristalsis, extend colonic transit times, and promote water retention [9] . With age therefore, the longer retention times and lower fluid volumes observed in the colon might balance out somewhat in terms of dosage form dissolution. In terms of interspecies comparisons, differences in colon physiology with respect to length, the presence or absence of furrows, transit times, and luminal pH values between rat, dog, pig, and human have been summarized [10] . Fig. 2 . is a summary of the main variables that can contribute to dosage form targeting and performance in the normal and diseased human colon, respectively. These factors need to be considered both when designing colonic delivery systems and in using preclinical models where comparative physiological differences in the colon will have an impact on performance. Many parameters can impact dosage form release and interaction with the epithelium and some can be exploited to trigger release. 1. Dosage form arrives intact and is affected by peristalsis (P). 2. Epithelial water flux impacts dosage form dissolution. 3. The potential difference (PD) may differ along the colon and in diseased states. 4 . Basal epithelial permeability to some ions and drug molecules may be higher in IBD; it is ion-and molecule-dependent. 5 . Mucus composition and thickness may vary along the colon and in disease states thereby impacting nanoparticle capacity to reach the epithelium. 6 . pH values vary in colonic regions, with a propensity for low values in the lumen of some UC patients. 7 . The colon has low amounts of fluid and this can mean variable dissolution. 8. Reactive oxygen species (ROS) can be produced in colonic regions in IBD; this can be exploited to release drug molecules from dosage forms. 9. The microbiome varies in disease and can be exploited to release drugs from metabolism-sensitive polymers. 10. Colonic transit is highly variable, and this means that release rates from dosage forms can be unpredictable if they rely on time. Note that these factors occur throughout the colon and that the numbers do not denote precise locations.
IBD and IBS
The disease processes in IBD pathologies alter colonic physiology. In active UC, the colonic luminal pH is considered somewhat more acidic in patients compared to normal subjects, however the original data is based on limited numbers of subjects and is not a consistent finding: pH values of 2.3, 2.9, and 3.4 were seen in just 3/6 UC patients, the other three UC patients having pH values no different from normal subjects [11] . A previous study in 11 UC patients was nuanced in its conclusion, with more acidic pH values detected only in the ascending colon compared to the same region in normal subjects [12] . Data from CD patients is inconclusive, but one study detected acidic pH values of approximately 5.3 in the ascending and descending colons of four patients compared to controls [13] . The rationale for the more acidic colonic pH in IBD may relate to an altered microbiome leading to increased production of lactic acid. Still, recent reviews [14, 15] assume that the colonic pH differences measured in some IBD patients are representative of the entire cohort. Moreover, the evidence was from studies where the accuracy of the measurements in the limited fluid volume of the colonic lumen was not determined and, moreover, it is likely that values will likely fluctuate with disease progression and severity. This is important because pH differences may need to be less variable if they are going to be relied upon as an approach for accurate colonic-targeting of macromolecules, and moreover, more acid pH values have implications for retaining macromolecule stability.
Other physiological differences between the human GI tract of IBD patients and that of normal subjects appear to be more consistent across cohorts. Patients display up to 20% longer small intestinal transit times [16] , an increase in colonic epithelial permeability (due in part to inflammatory cytokine action on tight junctions) [17] , reduced surface mucus (due to low numbers of goblet cells) [18] , build-up of cationic charge across the epithelial surface (due to over-expression of transferrin) [19] , and an altered microbiome [20] . Hua et al. [14] have highlighted that many IBD sufferers undergo resection of intestinal regions and that some of the consequences of a shortened bowel are altered luminal pH and transit times, impaired regulation of the ileal brake that controls food transit, and reduced small chain fatty acid digestion, each of which with associated implications for colonic dosage form design. While retention of the dosage form in the colon may be more challenging in IBD due to increased rates of bowel movements, delivery into the epithelium or to a downstream target may on the other hand occur more readily due to increased epithelial permeability. In addition, there are opportunities to exploit epithelial differences in surface charge to target macromolecule-entrapped particulates and hydrogels to promote retention in the IBD colon wall. Furthermore, apart from surface charge differences, there are also likely to be changes in receptor and transporter expression between normal colon and colon from IBD patients, as ascertained by immunohistochemistry for the decreased expression of P-glycoprotein and Breast Cancer Resistant Protein in UC [21] In the pathophysiology of IBS-C, diarrhoea-associated (IBS-D) or mixed type IBS (IBS-C, D), low grade colonic inflammation seems to occur in a subset of patients, and there is evidence of an overall reduction in numbers of intestinal endocrine cells and an increase in macrophages, however evidence for microbiome alterations in the colons of IBS patients is conflicting [22] . IBS is also associated with reduced GI transit times in women, linked perhaps to prostaglandin production during menstruation [23] .
Diarrhoea arising from GI infections
Diarrhoea is the ninth leading diagnosis in the ambulatory setting in the USA with over 2.5 million annual encounters with the healthcare system [24] . The problem is even more prevalent world-wide and diarrhoea is the second leading cause of illness in children under the age of five [25] . Disease-causing organisms span a range of bacteria, viruses, and parasites including enterohemorrhagic E. coli, Salmonella, Shigella, Cyclospora, Cryptosporidium, Giardia, Campylobacter Jejuni, C. diff.), caliciviruses, and enteric viruses. Pathogenesis can impact colon physiology and hence affect the performance of locally-acting dosage forms. Toxins can trigger signaling molecules including intracellular cyclic AMP/GMP and Ca 2+ to drive colonic electrogenic epithelial ion and water transport [26] . Cyclic AMP activates the cystic fibrosis transmembrane regulator (CFTR) on the apical membrane, and Ca 2+ similarly activates a Cl − channel [27] . Pathogens including enteropathogenic E. coli (EPEC) can also prevent Cl − reabsorption into the enterocyte via a toxin-independent process resulting in internalization of the Cl − /OH -apical exchanger [28] . There is also evidence that decreased Na + reabsorption into enterocytes also occurs in diarrhoea and is coupled to increased Cl − secretion. For example, cholera toxin mediates an increase in intracellular cAMP, which inhibits Na + uptake via the Na +− /H + exchanger and increases electrogenic Cl − secretion across the colon via CFTR [29] . Some of the main ion and water transport features of the colon are shown (Fig. 3) . Internalization of aquaporins occur at the peak of liquid diarrhoea in a rodent model and is a non-osmotic mechanism that contributes to the increased water content of colonic matter [30] . In addition, toxins secreted by intestinal pathogens may increase epithelial permeability [31] , which could lead to an altered concentration of the active pharmaceutical ingredient (API) in the colonic mucosa. For example, C. Diff. infections are a common cause of diarrhoea and can be a consequence of broad spectrum antibiotic therapy. In these infections, the colonic mucosa is exposed to two potent toxins, which bind to surface receptors, are internalized, and bind covalently to proteins of the RHO-subfamily involved in regulating of the F-actin cytoskeleton. The proteins are inactivated leading to cell-rounding, perturbed epithelial tight junctions, and eventually cell death [32, 33] . EPEC infections induce phosphorylation of myosin light chain, which leads to cytoskeleton contraction and increased tight junction permeability. The same study also showed a redistribution of occludin from the epithelial tight junctions to the cytosol [34] . Lastly, there is an increase in colonic motility in diarrhoea, which can lead to reduced retention of locally-acting dosage forms and hence incomplete drug release in an appropriate timeframe. Engaged pressure sensors will produce a bowel movement and propel matter forward, and there will be more bowel movements during an infection due to the larger intestinal matter volume [35, 36] . Like IBS, it is possible that bacterial overgrowth can increase colon motility in diarrhoea [37] . In terms of treatments, controlled-or triggered release of poorly-absorbed macrocycle antibiotics in the colon to treat C. diff. Infection would confer an advantage over current untargeted formulations. For example, the non-absorbable macrocycle antibiotic, rifamycin, is formulated as a controlled release system delivered to the colon and was recently filed in the EU to treat a range of bacterial infections (Table 2 ).
Colorectal cancer
Colorectal cancer is the third most common cancer in the world [38, 39] and is characterized by the development of malignant cells in the colonic epithelium. The interplay between the gut bacteria, immunogenicity of the cancer cells and pre-existing immunological conditions have a large influence on the tumor microenvironment [39] . Colon cancer often develops over 10 years with dysplastic adenomas arising from the colonic mucosa being the most common precursors [40] . In general, colorectal cancer is divided into the microsatellite stable/chromosomal unstable pathway and the microsatellite unstable pathway, the latter being primarily located in the ascending colon [41] . From a molecular pathway perspective, the activation of WNT signaling pathway and the de-activation of Transforming Growth Factor (TGF)-β signaling pathway results in increased activity of the MYC regulator gene which codes for a transcription factor and is associated with most colon and rectal cancers.
Sporadic cancers make up~50-60% of colon cancers in the US and, of these~70% follow the chromosomal unstable pathway in which large segments or whole chromosomes may be lost or duplicated, whilẽ 15% follow a pathway in which small changes in DNA at microsatellites result in cancer-causing genetic mutations [40] . About two-thirds of sporadic cancers arise distal to the splenic flexure, with about 40% arising in the rectum. The liver is the most common site of colon cancer metastases, present in ∼20-25% patient at initial diagnosis, with a further ∼25% developing them thereafter. Treatments for colon cancer include combinations of surgery, therapy and chemotherapy, the regimes dependent on stage and localization. Surgery is the main treatment for patients affected by local disease, often followed by adjuvant therapy for those where the cancer has spread beyond the mucosa. If there is more advanced disease, a colectomy is required which will alter the colonic physiology and local microenvironment, with an impact on future local therapies. Despite the advances in surgical procedures with less invasive procedures, local relapse occurs in ∼5-10% patients usually within first 2 years of surgery [42] .
The majority of chemotherapeutics for colon cancer are combinations of small molecule cytotoxic molecules administered via the intravenous (IV) route. Common regimens are FOLFOX: fluorouracil (5FU), folinic acid (also known as leucovorin), and oxaliplatin, and FOLFIRI: 5FU, leucovorin and irinotecan. Capcetabine (Xeloda®), an oral small molecule prodrug of 5FU, is also used. It was developed to improve the efficacy and tolerability of 5FU through its tumor-specific conversion to the active drug by thymidylate phosphatase, an enzyme with elevated levels in many cancers. In practice, capecitabine has improved tolerability but has similar efficacy to 5FU. In relation to moleculartargeted macromolecules, the anti-angiogenic, vascular endothelial growth factor (VEGF) inhibitors, bevacizumab (Avastin®), ramucirumab (Cyramza®) and Ziv-aflibercept (Zaltrap®), or the epidermal growth factor receptor (EGFR) inhibitors, cetuximab (Erbitux®) and panitumumab (Vectibix®) are being added to treatments as injectables. More recently, injectable immunotherapies (tremelimumab, pembrolizumab, nivolumab) have been explored in clinical trials with mixed results, however when segmented, disease of the ascending colon responds better, which has been attributed to more active immune cells in that region [39] . Harsh cytotoxic regimes have several side-effects including diarrhoea, which in turn impact release of locally-administered drugs. Early detection through colonoscopy and surveillance of genetic and IBD high-risk groups aims to identify early disease, which opens possibilities of earlier therapies and local delivery opportunities. Indeed, some companies are focused on colonic delivery of diagnostics for colon cancer detection: Cosmo Pharmaceuticals [43] are delivering methylene blue staining along the colon length using its MMX® colonic delivery technology to make it easier to identify polyps, small adenomas, and cancers via endoscopy. The role of neoadjuvant chemotherapy prior to surgery in locally-advanced resectable colon cancer is also under investigation [44] . Adoption of neoadjuvant therapies creates opportunities for local delivery and more specific therapies as disease understanding progresses, so avoiding non-specific debilitating chemotherapy prior to surgery. In addition, it may be possible to use local delivery post-surgery in some patients with limited spread rather than chemotherapyOverall, oral site-specific delivery of drugs should Fig. 3 . Cellular mechanisms accounting for colonic ion and water absorption and secretion. Some overlap with those of the small intestine (SI). Factors that reduce the amount or function of a specific transporter are shown in red boxes; those that increase levels of activity are shown in green boxes. Long vertical arrows indicate paracellular absorption or secretion of water. Glossary: DRA (PAT1): putative anion transporter; NHE3 (NHE2): sodium-hydrogen exchanger; ENaC: epithelial sodium channel; CFTR: Cystic Fibrosis Transmembrane Regulator; CaCC: calcium-activated chloride channel. LPA: lysophosphatidic acid; TK, tyrosine kinase; MAPK: Mitogen-activated protein kinase; KCC: potassium/chloride co-transporter; NKCC1: sodium/ potassium/2-chloride co-transporter. Reproduced with permission from [227] . Pre-clinical [93] [94] [95] result increased tumor concentrations in colorectal cancers and fewer side effects, and thus enable more efficient delivery of both small-and macromolecules for new and existing targets, and hence more efficacious therapy.
Colonic delivery of small molecules: learnings for macromolecules
Marketed small molecules using controlled release approaches for colonic delivery are primarily for IBD and include mesalamine, sulfasalazine, prednisolone, and budesonide (Fig. 1) . The rationale for regional targeting of 5-amino salicylate (5-ASA) moieties (e.g. mesalamine and sulfasalazine) were to prevent premature absorption of in the stomach and small intestine and to concentrate 5-ASA in the inflamed colonic region in either free or prodrug formats [45] . For corticosteroids, the rationale had an additional feature: local targeting to treat inflammation with the intention to reduce systemic exposure and associated side-effects [46] . In these examples the principles of dosage form design were based on identifying features of colonic physiology that are differentiated from the small intestine, as well as an understanding of GI transit times and inter-subject variability. Yet, even with the currently marketed small molecule colonic release products for IBD, there is still large inter-subject variability in the accuracy of delivery to the colon, as is described below in relation to specific formulation approaches.
Polymer-based drug delivery originated to encapsulate small molecules for release in regions of the GI tract, and there is an opportunity to leverage some of these technologies to protect labile macromolecules. Polymers can be designed from a range of monomers or comonomers to confer a variety of structures and architectures that give rise to properties useful for colonic delivery including the capacity to be triggered by physiological features of the normal-or diseased colon. Film coatings and coated pellet systems for small molecules have been recently reviewed [47, 48] . Systems targeting the colon typically are differentiated in the basis of GI transit times, inter-regional pH changes, bacterial enzymes, mucoadhesion, nanotechnologies and disease-associated triggers. Expanding methodologies to produce both micro-and nanoparticles as well as hydrogels have allowed elegant approaches for colonic targeting to be explored; Table 2 compares the polymers used for each of these trigger types for small molecules. From the following, it is apparent that colonic delivery approaches for small molecules is highly relevant for macromolecules.
Time-and pH-based triggers
Time-delayed systems are generally based on ethylcellulose polymers and several of these older systems are used to deliver small molecules to the colon. The inter-and intra-subject variability of gastric emptying limits the selectivity of this method of targeting, although a sustained release of 5-amino salicylic acid (5-ASA, Pentasa®) is marketed for the treatment of UC. This dosage form consists of microgranules of drug coated with a semi-permeable ethylcellulose membrane. 5-ASA is released slowly and at a consistent rate from the stomach onwards, but significant release in the colon is still low. The most commonly used pH-dependent polymers are poly(methacrylate)-based, i.e. Eudragit®. The Eudragit® coatings yield delivery system properties based on acid or basic groups in their structure and are designed to give different pH solubility profiles in intestinal regions. Both Eudragit S® and Eudragit L® are designed for colon targeting since they are respectively soluble at pH N 7 and pH N 6. However, as the pH drops in the ascending colon the molecule may not release if protected only by Eudragit S® and therefore combinations of Eudragit® S and L are often used [49] , although this can lead the converse of premature release in the small intestine.
For the treatment of UC, 5-ASA products containing Eudragit® coatings include Asacol® (Eudragit S®), Claversal ® and Salofalk ® (both Eudragit L®). A systematic study however, indicated large variability in release rate of tablets coated with Eudragit® S when subjected to the range of pH values present in the GI tract, highlighting a relative lack of specificity [50] . Furthermore, Schellekens et al. (2007) [51] also tested Salofalk®, Asacol®, and Pentasa® timed-release tablets and granules in a GI simulation system and showed that the percentage of the dose released in simulated colonic fluid was quite low for each. Variability in the in vivo release in humans of core tablets coated with Eudragit S® was also suggested from a gamma scintigraphy study in human volunteers [52] . Another study compared GI concentrations of 5-ASA from three colonic formulations of in healthy human volunteers: Pentasa® capsules (microspheres coated with ethylcellulose); Apriso® capsules (Eudragit L® coated granules) and Lialda® (multi-matrix delayed-release tablet coated with Eudragit S®). While the three formulations differed in their GI luminal concentrations of 5-ASA (and hence plasma profiles), similar concentrations of the primary 5-ASA metabolite were found in the faeces, thereby indirectly suggesting similar release and dissolution profiles from each formulation in the colonic region [53] .
To improve localisation to the ileo-caecal junction, a double coating method was designed, comprising an inner layer of Eudragit S® neutralised to pH 8.0, a buffer, and an outer layer of Eudragit S®. These tablets disintegrated more consistently in vivo compared to single-coated tablets, where disintegration was erratic, and mainly in the terminal ileum and at the ileo-caecal junction [54] . The accelerated in vivo disintegration of this double-coating Eudragit S® construct may overcome the limitations of conventional enteric coatings targeting the colon and can help avoid the pass-through of intact tablets. On the other hand, since the colonic luminal pH in IBD might be more acidic in some but not all IBD patients, such variability adds complication to the use of pH alone as a trigger for release.
Bacterial enzyme-based triggers
Polymers can release small molecules in response to the bacterial enzymes produced in the colon. Two classes dominate: the azoreductases and polysaccharidases. Polysaccharide-based polymers including pectin, chitosan, chondroitin sulphate, galactomannose, and amylose have generally regarded as safe (GRAS) status and are degraded by colonic bacteria [55] . Pectin, chitosan and glassy amylose have had the most success for small molecule delivery to the colon. Nevertheless, in their unmodified form, they do not have ideal properties of carriers, with neither the capacity to both fully protect macromolecules nor to form robust coatings for solid dosage forms in aqueous solutions. They have therefore been combined with film-coating materials or used in double coated formats to achieve improvements for small molecule and macromolecule colonic delivery.
Pectins are a family of heterogeneous polysaccharides composed mainly of D-galacturonic acid with its methyl ester linked via α (1-4) glycosidic bonds. The linear backbone of galacturonic acid units are interrupted by occasional neutral sugar residues such as rhamnose, galactose, arabinose, glucose, mannose and xylose. Pectin is sourced from citrus fruits or apple pomace and is isolated to produce pectins of varying degree of methoxylation, which determines its solubility and gelation properties. It is available in a range of molecular weights from 50 to 150 kDa, corresponding to several hundred to ̴1000 saccharide units. Pectin is not degraded by gastric or intestinal enzymes; however, it is readily broken down by pectinolytic enzymes produced by colonic bacteria. It has been explored comprehensively as a coating for tablets [56] . One of its main disadvantages is its high solubility where premature release of its cargo can occur, this can be overcome by using a high methoxy pectin potentially applied as a compression coat or low methoxy pectin in the presence of calcium ions which through crosslinking reduces the solubility of pectin and makes it more susceptible to enzymatic attack by pectinases in the colon [56] . One of its main disadvantages is its high solubility where premature release of its cargo can occur. Other strategies to reduce its solubility and to improve its coating capacity are to combine it with Eudragit® and hydrophobic film-forming polymers (ethyl cellulose or cellulose acetate). Examples include the entrapment of 5FU in pectin microspheres coated with Eudragit® [57] and of 5-ASA in pellets coated with pectin and ethyl cellulose [58] . In addition, small beads coated with a precise ratio of pectin to ethyl cellulose film and with a determined thickness suggested sitespecific delivery to the colon in both dog and human as measured by scintigraphy [59] . Tablets of several small molecule drugs intended for IBD treatment were coated with a mixed pectin and cellulose acetate coat along with a secondary coat of Eudragit® L100. The mechanism of release was due initially to dissolution of the Eudragit® coat, followed by degradation of the pectin creating micropores to enable near zero order drug release [60] . Further studies used chitosan to form a polyelectrolyte complex with pectin combined with hydroxymethylcellulose (HPMC) and localised delivery to the colon was evident from scintigraphy [61] .
Chitosan is obtained from the partial N-deacetylation of chitin. It is biodegradable and positively-charged at acidic pH. Like pectin, it needs to be combined with other materials to improve its properties to provide a robust coating and reduce its solubility in the upper GI tract. It has therefore been combined with Eudragit®, cellulose, and polyvinyl acetates. Chitosan/polyvinyl alcohol (PVA) (Kollicoat® SR 30D) mixtures were used to coat theophylline-and 5-ASA pellets [62, 63] and provided colonic release in rat studies. Chitosan was also mixed with cellulose acetate resulting in a semi-permeable membrane and tuneable osmotic release of budesonide [64] . Other approaches to prevent premature release have include the formation of polyelectrolyte complexes with other bacterial enzyme-susceptible polysaccharides including chondroitin sulphate [65] . In addition, chitosan-based pellets of rutin, (an aglycone prodrug of quercetin) have been in combined with sodium alginate, and following coating, demonstrated efficacy in a rat model of UC [66] . Recently, a double layer-coated colon-specific delivery system has been developed, consisting of a chitosan-based polymeric sub-coating of a core tablet containing citric acid for microclimate acidification, followed by an enteric coating of Eudragit E100® and ethyl cellulose [67] .
Amylose, the linear polymer of starch, has been exploited for colon targeting because its glassy amorphous form resists pancreatic α-amylase in the small intestine, while being fermented by the colonic microbiota. Glassy amylose in combination with ethyl cellulose was sprayed onto pellets containing 5-ASA with 13 C-labeled glucose [68] .
Following dosing to human volunteers, 13 CO 2 breath testing correlated with arrival of the pellets in the colon, and this was confirmed by scintigraphy. A similar amylose ethyl cellulose coating was used to coat prednisolone-entrapped pellets (COLAL-PRED ®) and completed a Phase III trial for the treatment of UC [69] (NCT00299013). A high amylose starch (Hylon VII) and ethyl cellulose (Surelease®) mixture was used to coat 5-ASA pellets for delivery to rabbit colon, yielding a delayed C max and T max that indicated that the coating had performed [70] .
Recognizing the differences in colonic bacterial populations and related enzyme activities in difference disease states, studies have identified polymeric film coatings that allow for drug targeting to the colon under pathophysiological conditions. Nutriose FB06® (a branched wheat dextrin with non-digestible glycoside linkages) and Pea Starch N-735 were combined with ethyl cellulose for their sensitivity to degradation by fecal samples from CD and UC patients and to media simulating the contents of the stomach, small intestine and colon [71] . These mixed films were then used to coat 5-ASA pellets and were investigated for their capacity to target the colon and treat rats with chemicallyinduced UC. The films revealed good colonic targeting and a better pharmacodynamic response than Pentasa® pellets [72] .
Synthetic azo-polymers have also been explored for colonic drug delivery using the abundant azo reductase enzymes as release triggers [7] . Straight chain azopolymers were used to coat budesonide-layered pellets that were in turn over-coated with Eudragit® L. When administered to rats with 2, 4, 6-trinitrobenzenesulphonic acid (TNBS)-induced colitis in rats, the pellets displayed higher efficacy than an oral solution or a rectal enema of budesonide [73] . Concerns over possible safety issues due to the chemistry involved and the need for organic solvents are the main limitations for use of azo-polymer approaches. Bacterial-and pH enzyme-triggered approaches have also been compared in human subjects when theophylline pellets were coated with either Eudragit S® or an amylose /ethyl cellulose combination [74] . The authors concluded that the bacterial enzyme concept provided more accurate colon-specific delivery than the pH approach. Finally, there is a combined approach in trials to achieve colon targeting from the same tablet as measured by scintigraphy in humans: an outermost Eudragit® S 100 coat overlying a bacterial-sensitive polysaccharide coat (Phloral™ [75] ). The latter offers insurance against failure of the pH-dependent polymer to completely dissolve in the event of the pH threshold not being met in some individuals. This approach was used in a successful Phase III trial for mesalazine [76] and the formulation is due for product launch in 2019. Furthermore, the double coated approach has flexibility to be used for both tablets and capsules.
Mucoadhesive approaches
Mucoadhesive systems are intended to keep the delivery system in intimate contact with the intestinal epithelial membrane, however the mucous layer turns over within 24-48 h in humans and may be altered in the diseased state. Mucoadhesion in the colon might be more successful than in the upper GI tract due to comparably lower smooth muscle motility and higher mucus residence time, although this might be offset by the slower transit of the dosage form. Several key properties of polymers for mucoadhesion have been identified. These include high molecular weight to promote adhesion between the polymer and the mucus, as well as optimum polymer chain length and flexibility to promote the interpenetration of mucus network (but still with a molecular weight range to allow drug diffusion). Additional factors include high viscosity, cross linking density, availability of adhesive bonds, appropriate polymer concentration, charge, degree of ionisation, degree of hydration and optimal pH for adhesion. Mucoadhesive concepts for drug delivery have been recently reviewed [77] .
Polysaccharides have also been widely investigated as mucoadhesives with potential for colonic delivery and these include alginates and chitosans [77] . Chitosan forms hydrogen and ionic bonds between its positively-charged amino groups and the negativelycharged sialic acid residues of mucin glycoproteins. Alginate is a linear and anionic polysaccharide derived from brown seaweed. It is composed of alternating blocks of α-1, 4-l-guluronic acid (G) and β-1,4-dmanurunic acid (M) units and is available in various grades. Its biodegradability, low toxicity, chemical versatility, pH-dependent solubility, capacity to form gels in aqueous media and its mucoadhesive nature are key properties that have led to its investigation for colonic drug delivery. The mucoadhesive properties of alginate are thought to originate from the initial wetting and swelling of the polymer providing intimate contact with the mucosa, followed by interpenetration and entanglement between mucin and the polymer chains, promoting hydrogen bond formation. The use of alginate in microparticles for oral delivery to the colon alone and in combination with other polysaccharides and/or pH sensitive polymers has recently been analyzed [78] .
Synthetic polymers including the Carbopols®, a copolymer of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol, Carbomer® (acrylic acid-based polymers) and thiolated polymers (thiomers) have also been investigated. Thiomers are modified versions of polymers such as chitosan, acrylic polymers, and alginates designed with thiolbearing side chains, which are capable of superior physical interaction with mucus due to covalent bond formation between the thiol groups and cysteine-rich subdomains of mucus glycoproteins compared to the parent non-thiolated polymer [79] . ThioMatrix (Vienna, Austria) is exploiting the potential of thiomers for the non-invasive delivery of a variety of drugs using a proprietary technology, although the clinical experience so far seems to be in ocular-and not intestinal delivery.
Adhesive pellets of 5-ASA have also been prepared with Carbomer® 940 and HPMC as the core materials and coated with Surelease® and Eudragit® S100 as the outer layer. These pellets were mucoadhesive, targeted to the colon, and efficacious in a rat UC model [80] . In a similar approach, thiolated chitosan/alginate composite microparticles coated by Eudragit S-100® were formulated for colon-specific delivery of 5-ASA and curcumin and were used to successfully treat a rat UC model, demonstrating superior mucoadhesive properties of the thiolated chitosan/alginate composites over non-thiolated ones [81] . It is important to emphasize that no oral mucoadhesive tablet-or capsule-based approach for the colonic delivery of any molecule has succeeded in clinical trials despite over 30 years of effort. In analyzing the possible reasons, it may be related to a combination of rapid mucus turnover, lack of predictive power from current animal models, and intra-subject variability in GI and colonic physiology.
Nanoparticles and hydrogels
Polymeric nano-based delivery approaches offer advantages over more traditional colonic dosage forms in terms of the potential for better targeting to and/or accumulation in inflamed tissues, either passively (biophysical targeting) or via addition of an active ligand, giving the possibility of improved localisation in diseased tissues. Oral nanoparticle delivery approaches for IBD have been reviewed recently [14, 82] in respect of the design, formulation, and their evaluation in preclinical studies. An optimal particle size may allow preferential interaction with diseased tissue and uptake by macrophages and other immune cells. The effect of size on fluorescent styrene particles (0.1 μm -10 μm) was investigated [83] and the smallest diameter particles bound more avidly to the inflamed colon of a rat UC model compared to healthy colonic tissue. Nano-formats have enabled the effect of surface charge to be investigated in respect of electrostatic interactions, with a trend suggesting that cationic nanoparticles adhere preferentially to negatively-charged mucus, whereas anionic nanoparticles seem to favour positively-charged proteins in inflamed colonic epithelia, however conflicting results have been reported. For example, it is well-known that there is heightened attraction of anionic surfaces of particle formulations to the cationic surface of the inflamed colon.
Work by the Rubinstein group demonstrated that twice as many anionic liposomes adhered to the inflamed colonic epithelium as neutral or cationic liposomes in the dinitrobenzene sulfonic acid (DNBS) rat model of UC [84] . The concept was advanced further when they showed superior efficacy of a group of anti-oxidants entrapped in anionic liposomes compared to unentrapped molecules in the same rat model [85] . This is discussed in detail with respect to peptides in Section 4.1.
More recently, biodegradable polymers are being investigated for colonic delivery. Poly-lactic acid (PLA) and poly (lactic-co-glycolic acid) (PLGA) have been mainly investigated. PLGA nanoparticles (100 nm) encapsulating the immunosuppressant, tacrolimus, penetrated three times more into inflamed colonic tissue compared to healthy tissue in a rat colitis model following rectal administration [86] . However, Schmidt et al. [87] demonstrated preferential accumulation of 3 μm-but not 250 nm diameter PLGA particles in inflamed lesions of the colon from patients suffering from IBD when the particles were administered via enema. The PLGA nanoparticles appeared to be transported across inflamed mucosal layers rapidly, whereas microparticles were retained at the mucosal surface. This is contrary to data in previous animal studies where smaller size appeared to lead to better accumulation, however the types and surface properties of those particles were different and there were species differences in intestinal surface area, lumen conditions, and mucosal physiology. The total fraction of PLGA particles retained in the Schmidt study was also much lower than seen in previous animal studies where, for example, up to 15% of injected dose was retained [83] . Studies on both how particles interact with the colonic epithelium in the normal and diseased state, as well as the experience to date with particle-entrapped small molecules have informed the design of modified particles for macromolecular delivery to the colon.
Challenges for all nanoparticle constructs designed for colonic delivery are to achieve acceptable drug loading, to avoid premature release, and to minimise burst-release profiles. To address these three hurdles, PLGA nanoparticles entrapped with budesonide [88] or curcumin [89] have been coated with Eudragit® S100 and afforded better colonic localisation and efficacy in a rodent UC model than the drug either in solution or suspension. That the surface coating of a nanoparticle is as least as important as its diameter and charge was demonstrated in a study where ethyl cellulose nanoparticles were coated with polysorbate-20 and the result was accumulation in the inflamed colon of the TNBS mouse model of UC [90] . Naeem et al. [91] designed a dual pH-and bacterial enzyme-release trigger by preparing polymeric nanoparticles with a mixture of azo-polyurethane and Eudragit S®: these particles were selectively distributed in the inflamed colon of rats, yielding 5.5 fold higher accumulation than those made solely with Eudragit S ®.
Another approach to generate a disease-triggered nanoparticle delivery system in the colon is to take advantage of high levels of reactive oxygen species (ROS) produced at sites of intestinal inflammation and in cancerous tissue. Biopsies taken from patients with UC have a 10-100-fold increase in mucosal ROS concentrations in inflamed lesions and these correlate with disease progression [92] . In cancer, the situation is further complicated since therapeutics (e.g. doxorubicin) may contribute to elevated ROS concentrations during induction of apoptosis. Two types of ROS-scavenging nanoparticles have been developed by Nagasaki's group: pH-dependent and independent. These "redox" nanoparticles were prepared via self-assembly of an amphiphilic block copolymer comprising nitric oxide radicals at the side chains of the hydrophobic segment. They are~40 nm in diameter with low poly dispersity and have high colloidal stability owing to the PEG shell. Orally-administered pH-independent nanoparticles accumulated in the inflamed colonic mucosa of mice, effectively scavenged ROS, thereby thus reducing inflammation in a mouse model of UC. They also inhibited the development of colitis-associated colon cancer in a mouse model in the absence of systemic absorption [93, 94] . The group also compared the efficacy of redox nanoparticles in combination with doxorubicin in a colitis-associated colon cancer model in mice and showed that the pH-dependent and pH -independent nanoparticles could improve drug uptake into cancer cells but not healthy cells, reduce adverse effects, and improve efficacy [95] . The results indicate that the combination of anti-oxidative nanoparticulate approaches with conventional chemotherapy could be a promising strategy for well-tolerated anti-colon cancer therapy. Macromolecules can potentially be added as components of these type of constructs.
Studies have also been carried out to ascertain the potential of lectins as ligands to improve colon targeting of nanoparticles. Wheat germ agglutinin and peanut agglutinin were covalently attached to the surface of PLGA nanoparticles entrapping budesonide and yielded enhanced bioadhesion to inflamed tissue and improved efficacy versus untargeted counterparts in a mouse UC model [96] . Coco et al. (2013) [97] synthesized mannose-functionalized PLGA nanoparticles, which had a~3-fold higher uptake in inflamed mouse colon tissue compared to controls. In addition, ligands for targeting enterocytes, M cells, and goblets cells can also be used to improve colon targeting of nanoparticles, however prevention of premature ligand exposure would be required to ensure site-specificity for the colon if the receptors are present throughout the GI tract. Despite the elegance of the actively-targeted nanoparticle approaches to achieve colonic localization, to date none have progressed beyond in vitro cell culture and rat studies.
Colonic delivery of small molecules via triggered hydrogels has also been explored. Targeting to inflammatory tissue can be achieved by taking advantage of the depletion of the mucus layer and in situ accumulation of cationic proteins including transferrin, anti-microbial peptides, as well as by exploiting increased epithelial permeability. The inflammatory process is accompanied by release of cytokines and extracellular matrix metalloproteinases. These features can be used for the electrostatic attraction of negatively-charged delivery systems incorporating a stimulus for release. For example, Zhang et al. [98] developed a hydrogel based on micro-fibers of the amphiphile, ascorbyl palmitate, which is capable of spontaneous self-assembly into a hydrogel. Dexamethasone was entrapped in the hydrogel and the resulting construct displayed an anionic surface, which was attracted to the cationic inflamed epithelial surfaces in vitro, to rodent colitis models, and to ex vivo inflamed colonic mucosae samples from IBD patients. Dexamethasone was released by enzymatic degradation and the system was more efficacious in a mouse UC model and less toxic than free dexamethasone administered via enema.
Colonic delivery systems for classes of macromolecules

Peptides and proteins
The challenges for oral delivery of peptides and proteins in the context of achieving systemic delivery have been covered recently in terms of approaches in clinical development [99] . Here, we address the potential of targeted colonic delivery of peptides and proteins where the approach is designed for treating the diseased colonic epithelium and/or subepithelial tissue. It is unclear whether leveraging the technologies used to date to deliver small molecules to the colon will suffice to deliver challenging labile macromolecules, but perhaps they can be adapted. The undecapeptide, cyclosporine (CsA, Mw 1203 Da), is in development for moderate-to-severe IBD using oral dosage formulations designed to reach the colon. It is a stable cyclic hydrophobic immunosuppressive and the marketed oral microemulsion (Neoral®, Novartis, Switzerland) has an oral bioavailability of 30-40% [100] . Unusually for a peptide, absorption of CsA is limited by solubility rather than permeability and it is also subject to its bioavailability being impeded by interplay between intestinal P-glycoprotein efflux and the cytochrome P450 3A family [101] . Oral CsA formulations that can deliver locally to the colon are being investigated as a treatment for severe UC. Intravenous (IV) administration of the calcineurin inhibitor is currently reserved for severe UC sufferers, who are non-responsive to corticosteroids and are potentially facing colon removal [102] . A Cochrane Library Review of the safety and efficacy of randomized clinical trials of injectable CsA concluded however, that while short term use could be beneficial in assisting steroid-refractory UC patients achieve temporary remission, chronic use was questionable due to limited evidence of efficacy and the increased risks of nephrotoxicity, hypertension, infection, and neurological side effects [103] . On the basis of more recent clinical data however, CsA is nowadays considered a valid alternative to infliximab in steroid-refractory UC patients [104] and the use of CsA for this condition has therefore become more common.
A Phase IV clinical trial (NCT00542152) in steroid-refractory UC patients compared efficacy of periodic i.v.-administered infliximab (Remicade®, Janssen, Belgium) with an initial i.v. dose of CsA, followed by daily oral Neoral® for three months, however the results have not yet been reported. The toxicological argument around the potential for nephrotoxicity to be caused by high blood levels of CsA is spurring efforts to formulate a colonic-delivered format with restricted distribution beyond the GI tract. Such locally-targeted formulations may also allow conversion of CsA from i.v. -to oral formulation for patients with lymphoma or myeloma who develop life-threatening autoimmune intestinal graft-versus-host disease following an allogeneic bone marrow transplant [105] . In such patients, the optimum route of delivery and the most appropriate GI region for presentation of CsA remains uncertain [106] , but nevertheless this might be a second disease scenario where delivery of CsA to the inflamed colon could be beneficial.
In devising approaches for local delivery of CsA to the colon, preclinical research has focused firstly on creating polymeric micro-and nanoparticulates to deliver CsA across mucus and into the epithelium. One of the first studies to stimulate this effort was when CsAentrapped PLA microparticles of diameters 1-5 μm at an oral dose of 0.2 mg/kg/day were administered by daily gavage for a week to the dextran-sulphate sodium (DSS)-induced murine UC model [107] . The particle formulation of CsA was more efficacious than free CsA with respect to histology scores and myeloperoxidase activity, but importantly, serum levels of CsA were much lower for the microparticle group. This study was built upon when efficacy of CsA-entrapped PLGA particles of both 160 nm and 2.7 μm average diameters was also demonstrated in DSS-treated mice following oral dosing [108] . In that study, plasma CsA concentrations were measurable for only the larger particles, thus presenting a toxicological argument in favour of using CsA-entrapped PLGA nanoparticles. A more complex nanocarrier construct comprised PLGA as a core polymer surrounding CsA, over-coated by Eudragit FS30D® [109] . These~250 nm diameter nanoparticles released the bulk of their CsA at pH 7.4 and were efficacious in the DSS mouse model of UC following oral delivery. Overall, these data were consistent with human rectal administration studies of UC patients to the effect that PLGA nano-and microparticles preferentially attach to the ulcerated colon per se [87] .
CsA is also suitable for entrapment in lipid-based nanoparticle systems. Guada et al. [110] describe efforts to entrap CsA in a group of lipid nanoparticle prototypes based on ratios of lipid: aqueous phase components. Following oral administration to the DSS mouse model, it was disappointing that neither these constructs nor Neoral ®were effective in reducing acute colonic inflammation in the model although studies on efficacy in chronic inflammation models have not been tested yet. Toxicity studies in normal mice following repeated oral gavage suggested some potential for reduced nephrotoxicity and lower blood levels from the CsA delivered in lipid systems compared to Neoral® [110] . It is worth noting that these lipid formulations were not designed for colonic targeting and could be re-visited in that regard.
Using other nanocarrier concepts to deliver CsA to the colon, Courthion et al [111] recently synthesized a CsA-entrapped selfassembled micelle nanocarrier composed of methoxy-PEG and hexylsubstituted PLA for rectal delivery to a mouse model of UC. With a diameter of 30-50 nm and a slightly negative zeta potential, the rhodaminelabeled carriers distributed preferentially into deep structures of the inflamed colonic tissue compared to normal mice, and the tissue concentrations of CsA-loaded counterparts were almost 5-fold higher than free CsA. Moreover, there was no evidence of systemic delivery of CsA by either the entrapped or even the free CsA delivered rectally over 7 days, a desirable outcome. No doubt, many other nanoparticle constructs designed for colonic targeting will turn out to be suitable for delivering CsA, but so far, they are limited to small molecules. One example of a receptor-targeting approach was the demonstration that mannosegrafted PLGA nanoparticles could deliver ovalbumin into the inflamed colonic mucosae from DSS-exposed mice in vitro [97] .
Nanoparticle concepts for locally-delivering CsA to the colon of UC patients are still at a relatively early stage and, so far, are largely predicated on excitement from data achieved in mouse UC models. To develop the CsA particle concept further ultimately depends on nanoparticles being protected in a suitably-coated capsule that can transit its way to the colon intact before releasing the particulate epithelial targeting technology. Colonic targeting of CsA in a solid-dose format containing self-emulsifying beads has been achieved in pigs using Sublimity Therapeutics' (Dublin, Ireland) SmPill™ technology [112] . It is based on an oil-in-water emulsion that forms 1.5 mm dried minisphere beads upon cooling in gelatin; the beads are then coated with pectin over Opadry® white to release in the colon. In the pig study of oral formulations, there was evidence of CsA concentrating in colonic tissue from the pectin-coated system, again with reduced levels of plasma CsA compared to Neoral® (Fig. 4) . Using the same technology but with barium as payload, pectin-coated minispheres could be seen on X-rays reaching the colon of rats intact following oral delivery, whereas ones coated with ethyl cellulose dissolved in the small intestine [113] . While the rat model confirmed colonic targeting with coated miniaturized minispheres, its use in developing a solid dosage form dependent on coatings for regional targeting of the intestine is somewhat limited. Such studies are technically very difficult to carry out, and, due to species differences in GI physiology, the larger diameter minispheres require an alteration in coating composition to achieve accurate release in the colons of higher animals and humans. A SmPill™ minispherein-capsule formulation of CsA (STI-0529) with colon-targeted minispheres similar in design to those used in the pig study completed a Phase II trial (NCT01033305) in 118 UC patients, however results have not yet been published. A summary of studies to achieve colonic targeting of CsA from oral-and (lower hurdle) rectal approaches is presented (Table 3) .
Other peptides are being assessed as potential therapeutics for UC. Vasoactive-intestinal peptide (VIP) is being examined as a potential therapeutic with the challenge to protect it from intestinal metabolism and formulate it for local colonic delivery. In the mouse and human colon, expression of the apical membrane-expressed VIP receptor, VIP receptor type 1 (VPAC1), seems to be higher than in other regions of the GI tract [114] . In a study examining colonic epithelia from UC patients, levels of mRNA for VIP and immunohistochemistry of the VPAC1 receptor were reduced compared to control epithelia mucosae [115] , but there is no consensus on VIP expression and its regulation as part of the enteric nervous system in the colon ( [116] ). Nonetheless, recombinant VIP was injected by the i.p. route on a daily basis and reduced inflammation in the TNBS rat model of colitis [117] . VIP was also entrapped in sterically-stabilized micelles and was tested following a single dose by the i.p. route in the DSS mouse model, where efficacy was again demonstrated [118] . Data from i.p. administrations needs to be treated with caution as it may reflect an effect on the colon from the peritoneal side of the colon. Nonetheless, rectal administration of micelle-entrapped-but not free VIP reduced inflammation and diarrhoea in the DSS mouse model of UC [119] , thereby demonstrating an action from the mucosal side of the epithelium. It is possible therefore that an oral controlled release of stabilized versions of VIP or VIP analogues designed to release in the colon of UC patients might be efficacious.
The bioactive natural tripeptide, Lys-Pro-Val (KPV) is isolated from the C-terminus of α-melanocyte stimulating hormone and has antiinflammatory actions [120] . In an early attempt to deliver it to the colon to treat colitis, it was formulated in PLA-based NPs with polyvinyl alcohol as a surfactant [121] . Subsequently, it was encapsulated in a hydrogel made of alginate and chitosan, which was hypothesized to collapse in the colon upon degradation of the polysaccharides. Daily gavage of the hydrogel was more efficacious than KPV in solution in the DSS mouse model of UC and the conclusion was that far lower concentrations of the peptide might be delivered to the colon in the hydrogel format. A further iteration was to entrap KPV in a hyaluronic acidbased polymeric nanoparticle in a hydrogel, where it also produced similar positive data following gavage [122] . KPV is transported into colonic epithelia by human intestinal peptide transporter 1 (hPEPT1), which is upregulated in UC and is associated with colorectal cancer. Studies in PepT1 knock-out mice or in transgenic mice over-expressing hPEPT1 revealed a role for KPV in preventing inflammation-linked carcinogenesis and that the beneficial effect was associated with hPepT1 downregulation [123] . New molecules to treat the different scales of UC must differentiate from the established therapeutics in terms of efficacy or side-effects. Colonic delivery can assist in this, but the concept of a Notes: Some formulations may also be leveraged for Graft-Versus-Host disease with intestinal complications. Approaches to increase systemic bioavailability of CsA in order to compete with Neoral ® were excluded.
peptide with additional potential to treat UC-associated colorectal cancer via a molecular target is of special interest. Another interesting example is the neuroprotective octapeptide, NAP (NAPVSIPQ, davunetide). This peptide was administered by the i. p. route daily from day 3-6 after induction by DSS and, while it did not alleviate macroscopic colonic inflammation, there was a reduction in pro-inflammatory signaling and in local T cell numbers in the inflamed intestine [124] . Though the data thus far does not suggest a major beneficial effect for UC from this initial study nor does it confirm a direct action on colonic mucosae, part of the interest is because NAP may have potential to be re-purposed from its main research area as a neuroprotective agent in CNS. If it was to progress as an injectable for UC, options for local colonic delivery could be examined. Another synthetic 37-mer peptide, gp96-II, was also administered by repeat i.p. injections to two murine models of UC, the TNBS and the IL-12/IL-18 models, representing acute and chronic inflammation scenarios respectively [125] . Gp96-II is an antagonist of the heat-shock protein 90, GP96, which is associated with inflammation via a selection of Toll-like receptors (TLR), including TLR-4. Disease activity scores, weight loss, and reduced colon damage morphology was detected in both models when the peptide antagonist was administered by daily i.p. injection to both murine models and the data was on a par with that seen with prednisone. With the caveat that a direct mucosal action of Gp-96-II is not yet confirmed, if so, it is likely to be too large to cross the intestinal wall, so perhaps local delivery to the colonic epithelium might be an interesting option if it can be protected during GI transit.
L cells in the intestinal epithelium produce endogenous pleiotropic peptides including GLP-1, GLP-2 and PPY. Apart from known benefits in managing Type II diabetes and obesity, there could be additional potential for GLP-1 and GLP-2 analogues as anti-inflammatories in IBD. Recently, the capacity of 200 nm diameter lipid-based nanocarriers (in the absence of a payload) to stimulate release of GLP-1 was demonstrated in mice [126] . Remarkably, the same group has confirmed that increased plasma levels of GLP-2 can be induced at 60 min following oral administration of selected lipid-based nanocarriers (again without a payload) to DSSexposed mice [127] . This is of interest because GLP-2 can protect the inflamed epithelium in the TNBS mouse model of UC it may do so by preventing a reduction in VIP-expressing enteric neurons [128] . In addition, a peptidase-resistant injectable analogue of GLP-2, teduglutide (Gattex®, Shire Pharma, Dublin), is approved to treat short-bowel syndrome and intestinal failure in patients [129] . Perhaps combinations of stable analogues of GLP-1 and GLP-2 can be delivered to the UC epithelium in a nanocarrier-protected format encompassing a range of lipids that in turn have the capacity to stimulate release of endogenous counterparts from L cells. A final point on the potential for nanoparticles to deliver peptides to the colonic epithelium was suggested by a study in which the intestinal fate of insulin-loaded nanocomplexes made from a range of excipients were studied using a range of in vitro and in vivo imaging techniques [130] . The main conclusion offered was that, although these particles did not deliver insulin to the circulation very well, one explanation was that they may accumulate in intestinal tissue and could therefore have a niche for local delivery to treat IBD with alternative payloads.
Efforts are also being made to improve the stability and efficacy of injectable small peptides with potential to treat UC by prolonging their half-lives and reducing both the injection burden and the concentration of peptide required. The anti-inflammatory tripeptide, MC-12 (Ac-GlnAla-Trp), is a motif derived from Annexin A1, and it down-regulates production of TNF-α, IL-6, L-10, and NFkB, but it is sensitive to serine proteases. It was revealed as an anti-inflammatory peptide following i.p., oral, and rectal administration to the DSS and TNBS mice models with several doses of 5 and 25 mg/kg during the induction phases [131] . CabosCeceres et al. [132] grafted it onto a cyclic 14-mer peptide scaffold made from sunflower trypsin inhibitor. It was administered by a single i.p. injection of the stabilized peptide at a single dose of 3 mg/kg ahead of induction of murine intestinal inflammation by TNBS. Due to the increased stability and potency, the cyclic version of MC-12 improved the parameters of weight loss, colon length, and activity score in the model compared to free MC-12. In this example, since it was resistant to trypsin, the modified peptide might be able to resist small intestinal attack and could potentially be a candidate for oral colonic delivery.
Antibodies
As with peptides, therapeutic monoclonal IgG antibodies are unstable at acidic stomach pH and are labile in the presence of intestinal peptidases. While systemic delivery from oral formulations is not a realistic option for antibodies due the poor permeability of such excessivelyhigh molecular weight and hydrophilic moieties, there is still potential for local delivery to the colon to treat inflammatory conditions and infections with the rationale of inducing less side-effects than the injectable counterpart. For anti-TNF-α antibody injections, potential side effects include an increase in the relative risk of common infections, tuberculosis, and lymphomas [133] . To lay the groundwork for such formulation design, it was recently shown that infliximab (Remicade®) and adalimumab (Humira®, Abbvie Pharma, Chicago) could survive better in human colon fluid compared to the small intestine and the stomach [134] . 50% or more of the two selected IgG 1 antibodies remained intact in the colonic buffer at 60 min, whereas metabolism occurred at 30 min and 1 min in buffers mimicking the small intestine and stomach respectively. The colonic stability advantage over the stomach and small intestine for these antibodies was ascribed by Yadev et al. [134] to low levels of serine proteases (especially elastase) along with higher pH values of around 7. Alternatively, IgG 2 antibody appears to be more stable against pancreatic peptidases than IgG 1 [135] , hence it may be a better starting point in terms of payload selection. Antibody targets in the colon include TNF-α, clinically established as an inflammatory mediator in IBD and CRC [136] , Toxin A and B for C. diff., and Shigella for bacillary dysentery (reviewed in [137] ) For infection due to C. diff., a multivalent antibody (Ab1) was produced in CHO cells and entrapped by spray-drying in mannitol beads coated with Eudragit® FS 30D [138] . Following a demonstration that the beads released 50% of the antibody at pH 7.4 and b 20% at pH 1.2, the multi-particulate formulation was tested by gavage in a hamster challenge model and protected the animals against weight loss versus control.
With lack of propensity to induce tolerance and a capacity to be produced in a range of species, non-humanized antibodies against GI targets can potentially be scaled up from milk for oral delivery [137] . If the capacity for production of industrial quantities can be addressed, outstanding issues are stability in the GI tract and release in the correct region, along with enough specificity and potency against an accessible target. The development of Avaxia Biologics's (Lexington, Mass.) recombinant AVX-470 has been reviewed [3] . It is a polyclonal antibody against TNF-α produced in cow milk and then formulated in an enteric capsule, ultimately intended for treatment of pediatric UC [139] . It takes advantage of the principle that antibodies produced in colostrum from mammary glands have increased stability in the neonate GI tract, can concentrate in colonic tissue once it reaches there [140] , and has limited systemic exposure thereby reducing capacity to immunosuppress. A first-in-man trial of AVX-470 (NCT01759056) comprised 37 patients with active moderate-to-severe UC, who were administered ascending doses daily in capsules over a month period in a randomized design [141] . The main outcome was a good safety profile, with some positive trends for several biomarkers of efficacy seen at the top 3.5 g/day dose. There was no indication that the capsules used in this study were specifically optimized for colonic release however, and it appears that AVX-470 is no longer in clinical development. On the other hand, lower molecular weight Llama-derived domain antibodies against TNF-α are in Phase II for CD using a colon-targeted oral formulation [142] . Using an alternative approach, this time for systemic delivery, an attempt was made to design capsules from HPMC-coated Intellicaps ® to release IgG 2 conjugated to a ligand targeting the FcRn receptor in the small intestine of cynomolgus monkey following weekly oral dosing [135] . While the study failed to show systemic delivery from a receptortargeting approach, it is the first indication that more advanced formulations are being researched for regional release of antibodies in the GI tract.
RNA therapeutics
There are two main strategies for RNA and related nucleotide therapeutics: inducing and inhibiting protein production in cells. If warranted, mRNA can be delivered to further the production of a desirable protein via translation by the ribosomes. However, in other cases the DNA message and the resulting protein production give rise to disease and inhibiting the translation would give rise to therapeutic benefit. The current main therapeutic approaches used to degrade mRNA and to down-regulate protein production are: 1) small interfering RNA (siRNA) and 2) antisense oligonucleotides (ASO). Relevant details on ASOs and siRNA for their therapeutic action and their cellular mechanism are shown in Fig. 5 . and in [143, 144] . While ASOs may not need delivery enablement to get into the cell per se, delivery systems may result in more productive uptake. Additionally if the ASO chemistry is such that it triggers immune responses, this may potentially be mitigated by formulation. Larger RNAs including siRNA and mRNA need a delivery system that would typically contain a cationic polymer, lipid, or peptide to promote endosomal escape and cytosolic bioavailability. In terms of local colonic delivery, the literature is focused on using siRNA and ASO modalities to treat IBD, IBS, and CRC. Table 4 is an overview of ASO and siRNA delivery approaches for these conditions citing ex/in vivo proof-of-concept (POC) in colon-relevant rodent models.
TNF-α is a pro-inflammatory cytokine secreted by macrophages and it has a central role in the pathogenesis of inflammatory disorders including IBD [145] , and is a prime target to inhibit via local colonic administration of siRNA/ASOs. Most of the studies cited in Table 4 have targeted TNF-α itself or in combination with inflammatory cytokines via siRNA. Study 1 (Table 4) reports that siRNA nanoparticles made from a mannosylated bioreducible cationic polymer were complexed using sodium triphosphate as a cross-linker [146] . These particles had reduced cytotoxicity in RAW264.7 macrophages and Caco2-BBE cells compared to those made from branched polyethyleneimine (PEI) or oligofectamine™. The complexed nanoparticles were also effective in reducing TNF-α secretion by macrophages and reduced inflammation in the DSS-induced mouse UC model [146] . In Study 2 [147] the authors used actively-targeted nanoparticles and reported that F4/80 Fabgrafted PLA-PEG particles displayed improved targeting to RAW264.7 cells compared to non-grafted ones. Results consistent with this were obtained when the nanoparticles containing the siRNA were administered to the DSS-induced mouse model, where the targeted particles reduced inflammation more efficiently than untargeted. Study 3 in Table 4 [148] investigated several different anti-inflammatory cytokine siRNAs (in addition to TNF-α) in PEI-coated calcium phosphate-PLGA nanoparticles and reported that the particles showed good epithelial uptake, minimal cytotoxicity, and evidence of gene silencing in primary cultures of mouse colonic crypt cells. Rectal administration of the particles to the DSS-mouse model led to a decrease of the target gene expression in colonic biopsies, accompanied by a decrease in inflammation. In Study 4 [149] a nanoparticles-in-microsphere oral system (NIMOS) system was investigated using TNF-α siRNA, and the constructs resulted in decreased production of TNF-α, interleukin (IL)-1β, interferon (IFN)-γ, and monocyte chemoattractant protein-1 (MCP-1 in the DSS mouse model. Study 5 [150] investigated particle-size effects and binding affinities of siRNA-loaded galactosylated trimethyl chitosan cysteine nanoparticles. They found that larger particle diameters were associated with low permeability across Caco-2 monolayers, along with high siRNA binding affinity, with a tentative conclusion being that large 450 nm particles may have more anti-inflammatory potential in UC than 200 nm ones when delivered from the luminal side of the colon.
Study 6 in Table 4 [151] investigated TNF-α siRNA-loaded thioketal nanoparticles, which were assessed following oral administration in the DSS mouse model. This polymer is resistant to acidic and basic environments but degrades when exposed to reactive oxygen species in inflamed tissues. The particles delivered their siRNA cargo selectively to the inflamed colonic tissues and down-regulated TNF-α. TNF-α production can also be inhibited via ASOs (Table 4 ). In Study 7 [152] , a cationic konjac glucomannan (cKGM)/ ASO nanocomplex was administered orally in the DSS mouse model, decreased local levels of TNF-α, and alleviated inflammation. A physical transfection method was investigated by [153] (Table 4 , Study 8). Naked TNFα siRNA was administered as a simple solution locally in the colon of mice with DSS-induced colitis followed by ultrasound transfection leading to a 7-fold reduction in TNFα protein levels in colonic tissue compared to siRNA without ultrasound, resulting in better control of colitis. The study also showed successful delivery of firefly luciferase mRNA to colonic tissues using this approach. This group has also successfully delivered microparticles to 100 μm depth ex vivo in colonic tissues. Anionic and cationic particles were delivered equally well using ultrasound as an enabler. The ultrasound treatment appeared to strip away the mucus and this may overcome any negative impact of particle surface charge [154] . There are other inflammatory mechanisms that can be targeted with siRNA in the colon. CD98 is expressed on the surface of intestinal epithelial cells and plays a critical role in controlling the innate immune system in the GI and is overexpressed in various colonic inflammatory conditions. Table 4 , Study 9 [155] , investigated CD98-siRNA loaded PEI-nanoparticles in the DSS mouse model. The PEI complexation aimed to protect the siRNA against nucleases, and the particles were found to be biocompatible and non-toxic. CD98 was effectively downregulated in colonic cells leading to decreased inflammation. In Table 4 , Study 10, CD98 siRNA PEI nanoparticles functionalized with a single-chain CD98 antibody had affinity for CD98-overexpressing intestinal cells and reduced CD98 and cytokine expression. In the DSS mouse model, these particles reduced CD98 expression in parallel with a reduction in colitis severity [156] . Table 4 , Study 11 investigated an anti-CD98 siRNA and curcumin combination in chitosan nanoparticles with and without hyaluronic acid (HA) functionalization. The HA functionalized particles were incorporated in a hydrogel and administered to the DSS mouse model and they inhibited over-expression of TNF-α and CD-98 and reduced inflammation more effectively than single agents [157] . Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) kinase is an upstream mediator of TNF-α action. In Table 4 , study 12, galactosylated trimethyl chitosan cysteine nanoparticles with the cross linker, tri(poly)phosphate were compared to N-trimethyl chitosan-cysteine-conjugated nanoparticles [158] . The in vitro (Raw 264.7 cells) and in vivo (DSS mouse model) oral data demonstrated that the former more effectively mediated Map4k4 gene knockdown and inhibited TNF-a production than the latter.
A decoy therapeutic system uses a double-stranded oligonucleotide (ODN) to competitively inhibit binding of transcription factors to target genes. In Table 4 , Study 13 [159] , an ODN targeted to NFkB was used to suppress cytokine gene expression. Studies in Caco-2 cells showed that chitosan-PLGA nanoparticles were more effectively taken up than PLGA ones. The chitosan-PLGA particles also efficiently reduced symptoms in the DSS rat model. Intercellular Adhesion Molecule 1 (ICAM-1) (or CD54) is an inducible transmembrane glycoprotein normally expressed on endothelial cells. Induction of ICAM-1 expression also occurs in colonic epithelial cells in response to cytokines and other mediators of inflammation. Table 4 , Study 14 [160] described ICAM1/CD54 ASO (ISIS 9125) administered rectally as a saline solution to the rat HLA-B27/2 microglobulin colitis model. Decreased inflammation symptoms were evident along with reduced expression of TNF-α, CD49d, and CD18 in colonic tissues. An ICAM-1 ASO for UC, formulated as a rectal enema, has also advanced to the clinic (Table 4 , Study 15 [161] ). Alicaforsen/ISIS2303 was administered in an open label study over six weeks to investigate colonic and systemic pharmacokinetics in 15 subjects, who received nightly ASO enemas in solution. Systemic bioavailability from the colon of ISIS2303 was b0.6% and there was a decrease in disease index and an increase in remissions. Table 4 only contains a single siRNA study for CRC using an ex vivo model. Study 16 [162] targeted the E2F1 transcription factor that plays a central role in cell cycle progression in normal and CRC cells. Cationic 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) nanoliposomes downregulated the E2F1 target in HT29 colorectal cells and, in addition, uptake and silencing were seen in cultured human colonic tissue mucosae. The cancer xenograft model typically involves implanting the tumor by the sub-cutaneous (S. C.) route, but it lacks physiological relevance for the colon. However, orthotopic models can be established where the tumor is in a relevant organ, but these models are technically difficult to establish, and this may explain why in vivo POC studies are not prevalent in the CRC literature for local colonic administration. Several ASO/siRNA studies aiming at CRC are instead using colonic cell lines and xenograft models, where the drug is administered by a parenteral route. While those studies cannot guarantee that these delivery systems will perform in the colon in vivo, a selected subset has been included in Table 5 for reference, mostly in terms of probing the biology.
The Vascular Endothelial Growth Factor (VEGF) dsiRNA (i.e. a more potent and stable class of siRNA) was entrapped in water soluble chitosan /pectin nanoparticles in Table 5 , Study 1 [163] . It was demonstrated that physicochemical properties, particle size and zeta potential, can be varied with dsiRNA/chitosan/pectin ratios. Release was low in simulated gastric fluid (SGF, b15%) and intestinal fluid (SIF, b30%) but much higher in simulated colonic fluid (SCF, N90%), due to presence of pectinases. Cytotoxicity studies in Caco-2 and CCD-18 CO cells showed increasing cytotoxicity with the concentration of pectin-coated and uncoated NPs, with the pectin-coated NP cytotoxic effect being slightly higher. In Table 5 , Study 2 [164] pursued the β-catenin target, which is increased in 70-80% of CRCs and associated with tumor progression. PEGylated chitosan NPs loaded with β-catenin siRNA were as effective as Lipofectamine® 2000 in reducing protein levels in colon cancer cells. Two studies in Table 5 ( Study 3 and 4) , are investigating siRNA-doxorubicin combinations in carboxymethyl dextran /chitosan nanoparticles. Study 3 [165] used siRNA targeted against SNAIL family transcriptional repressor 1 (SNAIL) in combination with doxorubicin. The results demonstrated that treatment with the dual agent nanoparticles led to down regulation of relevant genes, decreased cell migration, and cell death in HCT-116 cells. Study 4 (Table 5 ) [166] used High Mobility Group AT-Hook 2 (HMGA2) siRNA in combination with doxorubicin and showed that the nanoparticles induced HT-29 cell death and reduced expression of HMGA2. In Study 5 [167] , four and a half LIM domains 2 (FHL2) siRNA chitosan nanoparticles knocked down gene and protein expression at a similar level to siRNA transfected by Lipofectamine® in Lovo cells. In study 6 (Table 5 ) [168] , LoVo cells transfected with VEGF-C siRNA CaCO 3 nanoparticles conferred a reduction in VEGF-C expression. These particles were administered by the s.c. route in a xenograft model, and exhibited decreased tumor lymphangiogenesis, tumor growth, and lymph-node metastases. In study 7 (Table 5 ) [169] , Bcl-2 associated athanogene-1 (BAG-1) downregulation was investigated in Lovo cells via a plasmid DNA (pDNA) loaded onto gold NPs. Downregulation of BAG-1 gave rise to cell apoptosis in vitro and decreased tumor growth when the cells were injected into nude mice.
Finally, a series of mechanistic studies elucidating the fate of nanomedicines entrapping various types of RNA/DNA in the GI tract were conducted. Study 17 (Table 4 , [170] ) encapsulated enhanced green fluorescent protein pDNA in the NIMOS system. Both the NIMOS and the NPs not incorporated in NIMOS were associated with 111 Inlabeled gelatin, and were administered by gavage to mice where the NPs transited along the GI tract faster than the NIMOS constructs. The NIMOS particles only transfected regions beyond the stomach, thereby showing promise for local colonic delivery. Table 4 , Study 18 [171] studied the fate of GAPDH lipid nanoparticles (LNPs) containing siRNA in Caco-2 cells and in mice. The LNP transfection efficacy decreased following exposure to fed-GI conditions in the presence of pepsin, bile salts, and by mucin on Caco-2 epithelia. The latter effect could be circumvented by increasing the amount of PEG in the LNPs. In the mouse study, the LNPs were found to be retained in the GI tract for N8 h, but gene silencing did not occur despite confocal microscopy evidence of uptake by epithelia cells. The data confirm that protection is needed in the upper GI tract for orally-delivered LNPs to deliver their gene material to the colon. In summary, there is real potential for siRNA and ASOs to inhibit production of the disease-causing proteins in colonic disease states if they can be delivered appropriately. All siRNA studies to date used a nanoparticle formulation approach as enablement to enable cell uptake, endosomal escape and protein knockdown, whereas many ASOs were administered as simple solutions.
Cell-based systems
Probiotics are defined by the United Nations Food and Agriculture Association (FAO) and the World Health Organization (WHO) as live bacteria or microorganisms, which give rise to health benefits when dosed adequately [172] . There are currently no prescription probiotics available, but several are in clinical development for local colonic disease states (Table 6 ). The majority of probiotics are classified as nutritional supplements with or without health claims, and colonic delivery of probiotics spans pharmaceutical dosage form design and food science [173] . Naturally-occurring bacteria occur throughout the intestine, but they increase in density as content is moved down the gastrointestinal (GI) tract. Species composition patterns also modify from aerobic-in the upper GI tract to predominantly anaerobic in the colon [174] . Most probiotic compositions are intended to concentrate in the colon, but also for GI locations even outside of it. The main species are Lactobacillus and Bifidobacterium, both naturally located in colon [175] . Changes in the colonic microbiome have been implicated in IBS and IBD [176] , and this adds to the rationale of rebalancing altered bacterial ratios. Probiotics are also potential treatment options for dysbiosis associated with inflammatory conditions, as well as infection-related childhood diarrhoea, antibiotic-associated diarrhoea [177] , and C. diff. Infection [178] . In addition, probiotics seem to strengthen the host immune response, especially in neonates [179] , and recent data demonstrated that oral administration of Lactococcus lactis could reduce symptoms of acute cholera infection in mice through production of lactic acid [180] . It is important to recognize that there is no consensus on the merit of probiotic treatments, and a number of clinical trials to test efficacy did not reach their primary end-point, for example, [181] . Regardless of their as yet unproven therapeutic benefits, our focus here is on potential colonic formulation strategies since lack of efficacy could be related to sub-optimal delivery.
There are several formulation challenges for a potential probiotic product. These include 1) sufficient shelf-life; 2) protection against moisture, oxygen, and heat [182] ; and 3) equipping probiotics to survive the pH swings as well as digestion in the upper GI tract so that adequate concentrations of live bacteria reach the colon [183] . The first step in the formulation process is to reduce the bacteria to the solidstate using drying techniques such spray-, freeze-or fluid-bed drying. However, these technologies induce bacterial stress, and protective strategies are therefore needed to ensure survival. There are also economical aspects to be considered. Freeze drying is the best process in terms of bacteria survival but also the most expensive; it invariably requires addition of the cryoprotectants, trehalose or sucrose [184] . There are cheaper thermal drying alternatives (e.g., fluid bed drying, spraydrying), but they result in lower viability. Options include controlling the drying process and including protective excipients to reduce moisture in the final product and to preserve the viability. Temperature is usually the main culprit, and therefore selecting equipment that allows for temperature control (e.g., fluid bed drying) should be considered [182, 185] . Even when the bacteria survive the drying process, the functionality of the produced dehydrated probiotics can still be impacted. In a study measuring the impact of three drying processes (air-drying, freeze-drying and spray-drying) on three types of probiotics (Bifidobacterium Bifidum, Lactobacillus Plantarum, and Lactobacillus Zeae), the various drying processes gave rise to varying viability and intestinal epithelial adherence. Adherence was promoted by air-drying, but inhibited by spray-drying [186] .
The next step after bringing the bacteria to the solid state is formulation development. In one study Lactobacillus Gasseri and Bifidobacterium Bifidum, along with a prebiotic, quercetin, were coencapsulated in chitosan-coated alginate microspheres, but the yield of viable cells was low. When the two probiotics were encapsulated separately in microspheres however, they were stable in gastric and small intestinal conditions [187] . A dual coating approach has been developed for lactobacilli that gives a 100-fold better protection over the uncoated equivalent. The two layers include a pH-dependent protein layer (allowing the bacteria to remain coated at stomach pH), but then to release in the intestine at neutral pH, and a second polysaccharide matrix coating that protects the bacteria against environmental stressors including pressure, temperature and humidity [183] . Microencapsulation (i.e., in polysaccharides or protein matrices) and coating techniques can be used to keep bacteria protected from the GI environment [172, 188] . Encapsulation of probiotics in size 0 capsules coated with the Phloral® system comprising bacterial-activated starch and Eudragit S components enabled 90% survival in simulated GIF, along with rapid release in a buffer at pH 7.4, a pH likely to be present in the lower small intestine and colon [189] . The Phloral® colonic targeting system is also being investigated for its capacity to deliver fecal material to treat C. diff. Infection as an alternative approach to achieving fecal transplantation [190] . Finally, other types of formulations are being researched for encapsulating probiotics so that they can reach the colon intact. One example is a nanocellulose gel comprising gelatin and lactobacillus rhamnosus GG [191] . Since bacteria are sensitive to physiological and environmental conditions, and there is a need for quality control, typically by plate counting. Three probiotic dairy products (Imunele®, Dannon®, Pomogayka®) contained Lactobacillus Bifidobacterium in a concentration of 10 7 CFU/ml, consistent with the label claim [192] . On the other hand, in the Dodoo et al. study [189] , all of the commercial products tested were highly labile in GIF and the concentration of viable bacteria reaching the colon and adhering to the epithelium bore no relation to the starting concentrations in the product. Caution should also be taken when selecting quality control methods, as the standard plate counting methods can underestimate cell numbers. Drying and encapsulation may cause probiotics to enter a non-culturable, but still metabolically-active state. Molecular biology assays to quantify viable bacteria include polymerase chain reaction (PCR) and cell sorting techniques such as flow cytometry and fluorescent activated cell sorting (FACS). These approaches to quantification have been adopted in official guidelines and recently a new ISO guideline was launched to quantify lactic acid bacteria via flow cytometry [193] .
Recently, an additional application of probiotics has emerged: genetically engineering bacteria to produce macromolecules in the colon. This presents additional delivery challenges arising from the insertion of genetic material into bacteria and generation of stable expression in the colon region. Macromolecules are too large to be internalize into cells passively and therefore cannot normally locate to intracellular targets. To achieve uptake by bacteria, electroporation and transfection agents can be used, and, to mediate delivery at the desired location, a guide is needed (e.g., a plasmid or a transposases/recombinases) [194] . Recently, Lactococcus lactis was engineered to produce IL-10, which controls intestinal inflammation by inhibiting activation of dendritic cells [195] . With respect to colon delivery of anti-IgG antibodies against TNF-α, Lactococcus lactis was engineered to secrete murine TNF-α heavy-chain camelid stable "Nanobodies" [196] . Daily oral administration of the engineered probiotic achieved delivery of nanobodies against TNF-α in the colon of DSS-induced mice and reduced inflammation both in that model, as well as in interleukin 10 (IL-10) (−/−) mice. Similar data was also achieved in the DSS model using modified L. lactis to release anti-inflammatory trefoil factor peptides in the colon following intra-gastric administration [197] .
The CRISPR cas-9 system that is currently being advanced for therapeutic gene editing (i.e. a guide RNA plus a cas 9 protein, the latter functioning as the scissor editing the genes and the guide RNA required to find the right location for CAS9 to cut) can also be used to geneticallyengineer probiotics to deliver macromolecules and enhance host immune responses. The CRISPR Cas-9 system can also be used to modify probiotic strains to be more amenable to formulation processing and GI survival such as acid and bile resistance [198] . Genetically -engineered probiotics for pharmaceutical purposes is an emerging field and guidelines to fully ensure their safety will be required. The food industry has already built significant knowledge in this area [199] , which would serve as a good starting point for a pharmaceutical guidance. Finally, colonic delivery of vaccines represents another class of molecule that, like probiotics, falls outside the traditional pharmaceutical macromolecule definition. One aim is to generate oral colonic vaccination approaches specifically against viruses that invade via the rectal route, e.g. HIV. Zhu et al. [200] entrapped a range of vaccinia-related antigens, as well as luciferase-expressing DNA plasmids into PLGA microparticles coated with Eudragit® FS30D and demonstrated antigenspecific T cells activation in the colon following particle uptake by colonic epithelia following oral administration. Subsequent efforts at colonic immunization using particle approaches for bacterial antigens include entrapment of hepatitis B surface antigen in nanoparticles made of ratios of Eudragit® S-100 and L-100, along with an adjuvant [201] The argument for colonic vaccination is that local mucosal protection can be generated in respect of potent humoral and cellular immunity in the colon, rectum and vagina through the common mucosal system.
Development challenges for colonic macromolecule delivery
Considering the therapeutic potential for local macromolecular colonic delivery, it is surprising that there are not many candidates in clinical development. Relatively little has been published on the selection, optimization and development of colonic delivery systems designed for macromolecules pertaining to a realistic pathway for clinical development. To achieve a successful colonic macromolecule product, it is necessary that the delivery system is an integral part of the target product profile. Successfully translating colonic targeted delivery systems, particularly those designed for local delivery from pre-clinical proofof-concept to demonstration in clinical trials is challenging. Therefore, it is important to learn from other areas of drug development where target-driven design and patient stratification have improved patient outcomes. Advanced drug delivery R & D strategies might therefore build on the recent success of a drug discovery and development approaches, which have been improved by applying a focused decisionmaking framework. For example, application of AstraZeneca's (AZ) "5R" Framework uses five determinants: right target, right exposure, right safety, right patient, and right commercial potential. It has had a significant impact improving the success rate from AZ candidate nomination to Phase III from 4% in 2005-2010 to 19% in 2010-2015 [202] . A similar framework could be established for enhancing advanced drug delivery systems translation and performance and it would be particularly important for functional and targeted systems. Building informative data packages to answer these questions for local colonic delivery systems require: (i) an improved understanding of the heterogeneity of clinical disease and of the biological factors influencing the behaviour of the delivery system and macromolecule in the patient disease setting, leading to "disease led design," (ii) the implementation of relevant preclinical models and testing protocols, (iii) better techniques to measure exposure at site of action/in colonic tissue since plasma PK will not be a surrogate for efficacy, and (iv) careful choice of patient population.
"Developability Assessment" work-flows are used in the pharmaceutical industry to guide selection of a drug candidate and/or the delivery system in a serial or parallel fashion, an exercise frequently taking place early in preclinical research at the interface between Discovery and Development. Such work-flows have been designed for immediate release oral formulations of small molecules and peptides intended for systemic delivery [203] [204] [205] [206] [207] . These assessments can be adapted to encompass local colonic delivery, an example here being for nucleotidebased therapeutics where an early development delivery system "developability" assessment has not yet been published to our knowledge. Due to the limited progression of nucleotide-based therapeutics into clinical development, all publications concentrated on the research and preclinical space. A summary of these studies based on siRNA and DNA is provided (Table 7) . Not all elements needed for a developability assessment can be found in the nucleotide literature, and hence elements from the small-molecule literature were also considered. As illustrated, a nanoparticle system is commonly selected to enable colonic intracellular delivery for the major colonic-associated diseases. On the product quality side, assays to confirm delivery system formation and entrapment efficiency, along with chemical, physical and enzymatic characterization, as well as stability assessments are included in many publications.
The product performance assays in Table 7 were divided into in vitro assessment including release assays, disease-relevant cell and tissue uptake studies, and in vivo studies. In addition to information in Table 7 [208] is a recent review of colonic cell culture models. It is noteworthy that data generated in differentiated cell lines may not always translate, and hence primary cells, organoids or ex vivo tissues may be more appropriate. In vitro release assays have been developed for assessing local colonic delivery of small molecules. In a study of a dendrimer entrapping 5-ASA in a chitosan hydrogel designed for colon delivery, a staged dissolution approach was used to simulate transit through the GI tract, with the first hour in SGF (pH 1.2), the next two hours in mixed SGF and SIF to mimic the duodenum, then two hours in SIF (pH 7.4), and finally three hours in simulated colonic fluid (SCF, pH 7) [209] . The study screen therefore selected the formulation that had the least intestinal 5-ASA release in advance of reaching the colon. A related in vitro release assessment was used in a study of HPMC-coated colonic release tablets of ketorolac tromethamine using buffers of various pH values [210] . This study also illustrated the need to conduct appropriate stability studies on solid dosage forms, whereby HPMC-coated colonic release tablets of ketorolac tromethamine, were assessed conducted according to International Conference on Harmonisation (ICH) guidelines at 40°C and 75% relative humidity for 6 months. In another study, a SMEDDS (self-microemulsifying drug delivery system) containing prednisolone was used for colon-specific delivery. USP II dissolution in low pH (pH 1) and in phosphate buffer (pH 6.8) was used to measure release [211] . A standardised dissolution system for assessment of colonic drug delivery systems was developed by Goyanes et al. [212] by using a physiological bicarbonate buffer under dynamic pH conditions. It was established with an Auto pH™ System, which modulates and maintains the buffer at preselected pH values mimicking conditions along the GI tract. The performance of the model was validated with an enteric dual layer prednisolone formulation (internal standard) where in vitro release patterns correlated with the in vivo targeting performance in humans.
Given the diversity of such release assays, the composition of SCF was determined based on analysis healthy human volunteer-aspirated colonic fluids [213] . The solubility of ketoconazole, danazol, and felodipine was compared in SCF (fasted and fed) and standard buffers: the solubility in SCF more closely predicted solubility in human colonic fluids than in buffers. Hence, SCF constitutes a suitable vehicle for developability studies. TNO (Leiden, NL) (gastro-) Intestinal Models, ("TIM"), also provide insight into the release and availability of formulations along the GI tract. TNO has recently developed "TIM-2" as an in vitro model of the colon, which can be used in conjunction with the TIM-1 model of upper GI tract [214] . TIM-2 has been used to explore the site specificity and bioaccessibility to the colon and to assess delivery system performance. The optimized system is inoculated with microbes and metabolites from healthy-and diseased individuals and the resulting data has correlated well with clinical trials. As an example of assessment of compatibility with local drug delivery to the colon, Tannergren et al. [215] evaluated an in vitro method to investigate bacterial-mediated luminal degradation of drugs in human colon as a tool for early development assessment of drugs; this approach can also be applied to macromolecules. The preclinical studies cited in Table 7 used rodent models, but for practical reasons the nanoparticle formulations are not usually formulated into solid-dosage forms for these species due to the constraints of rodent model physiology. In the small molecule literature, additional stability studies are conducted on solid dosage forms designed for humans. Thus, in the example of HPMC-coated colonic release tablets of ketorolac tromethamine, stability was conducted according to ICH guidelines at 40°C and 75% relative humidity for 6 months [210] .
Regarding in vivo performance assessments for colonic delivery, aside from rare examples using live whole animal imaging of electrondense or fluorescent materials [114, 148] , the rodent studies cited in Table 7 were terminal and involved removing mucosae for analysis. Conducting colonic biopsies from large animals and humans, while feasible, is slow and expensive. Therefore, other in vivo testing options are needed to optimize local colonic delivery systems for clinical development. Plasma PK feedback used to optimize oral delivery systems intended for systemic exposure is not very informative for colonicallyacting macromolecules, except to confirm indirectly that they do not reach the blood. Several approaches to monitoring intra-luminal behaviour of oral dosage forms can be leveraged for studying the fate of colonic dosage forms (Table 8) . Intra-luminal sampling is useful to determine drug concentrations along the GI tract, as was exemplified in a recent study where a catheter with ports was used to withdraw samples for quantification of mesalamine in the various GI regions [216] . Telemetry is a related technology that can also be used for local colonic developability studies, an example being a formulation of ziprasidone, an antipsychotic small molecule [217] . In this study, the Enterion™ capsule with 111 -indium was used with scintigraphy to follow capsule progress throughout the GI tract. Telemetry capsules have also been used for assessing macromolecule release in GI regions. The Heidelberg capsule was tethered to an enteric-coated capsule formulation of salmon calcitonin. The pH values measured by the capsule were correlated to systemic PK and used to determine the site of release [218] . The Intellicap® system was also used to deliver an IgG 2 monoclonal antibody intended to bind to the FcRn receptor in the GI to mediate systemic uptake [135] . The study set out to use cynomolgus monkeys, however, in an initial screening study to measure gastric retention, it was judged too variable and hence beagle dogs were used instead. The capsule was used to dose the antibody and to measure intestinal PK profiles after administration in an enteric-coated capsule.
The advantages of the intraluminal sampling technologies include the capacity to obtain real time concentration measurements and to analyze the physicochemical status of the molecule (e.g. precipitate, complexation). The disadvantages include the invasive nature of the procedure: catheter approaches are perceived as unpleasant without sedation. Moreover, many of the technologies cannot be used across species since many catheters and telemetry devices are too large for Selected definitions: DsiRNA: Dicer small interfering ribonucleic acid; MP: Microparticle; NP: Nanoparticle; siRNA: Small interfering ribonucleic acid. Table 8 Overview of technologies that can be used to track intra-luminal dosage forms in large animals and humans (adapted from [223, [240] [241] [242] Magnetic resonance imaging (MRI) [222, 224, 225, 248] rodent species and, in addition, many of the telemetry capsules have limited volume. Lastly, the approaches do not allow study of kinetic aspects of dissolution and they usually require the use of another technology for precise location in the GI tract. With respect to technologies using radioactivity, examples where gamma scintigraphy was used to monitor release of dosage forms in the colon includes several small molecules intended for colonic were described earlier, while others are referenced in Table 8 . Since gamma scintigraphy can have issues with image resolution, other advanced imaging methods have been developed, albeit assessed with small molecules to date. Lai et al. studied prednisolone in colonic controlled release tablets for human volunteers, containing 99m Tc, an inner alginate layer, and an outer pH sensitive coat, in human volunteers using a hybrid scanner combining SPECT (single-photon emission computed tomography) and CT (computed tomography). The study recorded images of the disintegration process, and the newer imaging technologies were judged superior over gamma scintigraphy as regards locating the exact position of the dosage forms in the GI tract [219] . In summary, these technologies are useful in recording kinetic dosage form behavior in the colonic lumen, but on the other hand, they have disadvantages in that they require the use of radioactive labels and advanced equipment.
While gamma scintigraphy and related technologies are by far the most common to visualize the release of dosage forms intended for local or systemic exposure via the colon, other imaging technologies focus on X-ray detection. Flurbiprofen tablets containing barium sulphate as a contrast agent were prepared by direct compression and then coated with Eudragit® 100 and hydroxypropyl methylcellulose. In vivo release in healthy volunteers showed that the tablets reached the colon and did not disintegrate in the upper GI tract [220] . X-ray imaging using barium sulphate was also used to monitor release of flurbiprofen from pH-sensitive colonic-targeted tablets [221] and ketorolac tromethamine from colonic release hydroxypropyl methylcellulose tablets [210] . A useful technology to track regional delivery in the GI tract is breath/urine analysis ( Table 8 ). The concept measures radiolabeled additives (e.g. urea or glucose) or their metabolites in the breath or urine. For example, a controlled release ColoPulse™ tablet containing 13 C-urea was ingested by each subject along with an immediate release tablet containing 15 N-urea. The ColoPulse™ is a pHresponsive tablet technology that delivers a drug to the ileo-colonic region, a region rich in ureases that metabolize [ N -urea from uncoated tablets in the small intestine led to excretion in urine, and hence the location of the two tablet forms can be distinguished [222] .
Finally, magnetic resonance imaging (MRI) monitors protons and is therefore best suited to monitor organ and fluid volumes, but there are only a few examples describing the use of contrast MRI to follow the progress of colonic dosage forms [223] . In one study the GI distribution of a phosphatidylcholine liposome formulation containing the contrast agent gadolinium tetraazacyclododecane tetraacetic acid (Gd-DOTA) was followed by MRI. Liposomes were identified by the increased signal intensity provided by the contrast agent. Stability studies were performed to ensure the intactness of the liposomes under GI-relevant conditions [224] . A similar strategy was used in a study evaluating three immediate release tablets with different densities. In this case superparamagnetic Fe 3 O 4 particles were added to the tablets, and MRI used to analyze stomach tablet position and residence time in human volunteers. In the same study a slow release tablet incorporated Gd-DOTA to allow the GI locations to be followed by MRI [225] . Based on the review of the RNA research literature (Table 7) , the analysis of quality and product performance of selected colonic delivery technologies for small molecules, and our own development experiences, we propose a developability workflow to select colonic delivery systems for nucleotide-based therapeutics (Fig. 6) . The workflow can be used as a decision tree, where the researcher can revert to earlier stages for additional evaluation. It is theoretical at this stage and should therefore be verified with data from nucleotide-based formulations ear-marked for clinical development.
Conclusions and future perspectives
Developing dosage forms for local delivery of macromolecules to the colon to treat IBD, IBS, colorectal cancer, and infections is not simply a leveraging of the strategies already used for the limited range of small molecules that have been marketed as colonic release systems. Neither is it a fallback position in response to any failure to achieve systemic delivery for macromolecules, nor is it merely a life-cycle management approach for injectable macromolecules. The advantages of the approach are many, including the opportunity to treat early disease, avoid systemic toxicity of the candidate, the relatively accommodating environment for macromolecules in the colon compared to the upper GI tract, as well as the convenience for patients over injectable delivery systems.
Nonetheless, the technical hurdles to achieve accurate and reproducible colonic delivery of macromolecules are high. Intra-subject and inter-disease variability in GI physiology, overly-complex multifunctional component dosage form design, inadequate loading, incompatibility between the macromolecule and the dosage form, and variability in the triggering of release in the colon all combine, and the result is that there are relatively few macromolecule examples in oral clinical development or on the market. Consequentlythere is a lack of regulatory precedence and limited operational, scientific and clinical development experience. There is clear potential in exploiting particulate technologies for many colonic disease states discussed here. Much focus is on UC where there is evidence of selective passive targeting and localization of nanoparticles containing macromolecules to the inflamed epithelium, influenced by particle composition, diameter, and surface coating. The next phase of this research requires delivery of the nanoparticles containing amino acid-based and nucleotide-based medicines to be delivered to the colon in solid dosage forms because they can only interact with the epithelium if they reach the region intact in the first place. These dosage forms in turn will benefit from combination approaches, for example, the continued use of Eudragit® coatings allied to exploitation of bacterial enzymes to ensure release of the nanoparticles. As a companion to some of the research discussed in this article aimed at macromolecules, we note that ADDR has just published a detailed analysis of how biodegradable polysaccharide-coated systems can be used to target the inflamed colon [226] .
For antibodies and probiotics, the challenge is not to achieve high colonic tissue levels, but to act in the colonic lumen. This can also be achieved using solid dosage forms with combination approaches to ensure accurate and reproducible release, however these payloads have their own special needs related to ensuring entrapment of very high molecular weight proteins (antibodies) and high cell viability (probiotics), and both at the required dose levels. Finally, the developability aspects require earlier use of large animal distribution and imaging studies to support the rodent models, accompanied by addressing the reproducibility, scale up, and manufacturing questions around the selected colonic delivery technology. Colonic delivery system assessments will also have to discover alternative read-outs to evaluate preclinical and clinical performance, as the goal will not be addressed by measuring plasma concentrations. We are confident that the significant advantages will outweigh the hurdles and that a selection of macromolecules intended for local delivery to the colon will reach clinical pipelines in the near term.
